Kindred Biosciences (KIN) Receiving Somewhat Positive Media Coverage, Analysis Shows

Media stories about Kindred Biosciences (NASDAQ:KIN) have been trending somewhat positive this week, according to Accern Sentiment. Accern identifies positive and negative news coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Kindred Biosciences earned a media sentiment score of 0.19 on Accern’s scale. Accern also assigned media headlines about the biopharmaceutical company an impact score of 44.8316434275542 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

Shares of KIN remained flat at $$8.45 during mid-day trading on Friday. The stock had a trading volume of 39,165 shares, compared to its average volume of 101,697. Kindred Biosciences has a 12-month low of $6.50 and a 12-month high of $9.80. The company has a market cap of $238.20, a PE ratio of -6.87 and a beta of 0.08.

How to Become a New Pot Stock Millionaire

Kindred Biosciences (NASDAQ:KIN) last issued its quarterly earnings results on Thursday, March 1st. The biopharmaceutical company reported ($0.35) EPS for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.02). research analysts forecast that Kindred Biosciences will post -1.5 earnings per share for the current fiscal year.

KIN has been the topic of several research reports. HC Wainwright set a $11.00 price objective on Kindred Biosciences and gave the company a “buy” rating in a research report on Friday, March 2nd. Zacks Investment Research cut Kindred Biosciences from a “hold” rating to a “sell” rating in a research report on Wednesday, March 7th. Aegis reaffirmed a “buy” rating on shares of Kindred Biosciences in a research report on Friday, December 15th. ValuEngine raised Kindred Biosciences from a “sell” rating to a “hold” rating in a research report on Friday, February 2nd. Finally, BMO Capital Markets reaffirmed a “hold” rating on shares of Kindred Biosciences in a research report on Friday, December 22nd. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and four have issued a buy rating to the stock. Kindred Biosciences currently has a consensus rating of “Hold” and a consensus target price of $9.79.

In related news, insider Richard Chin sold 20,000 shares of the company’s stock in a transaction that occurred on Monday, April 2nd. The stock was sold at an average price of $8.39, for a total value of $167,800.00. Following the transaction, the insider now directly owns 2,266,071 shares of the company’s stock, valued at approximately $19,012,335.69. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Raymond Townsend sold 2,670 shares of the company’s stock in a transaction that occurred on Friday, March 16th. The shares were sold at an average price of $9.45, for a total value of $25,231.50. Following the completion of the transaction, the director now directly owns 25,057 shares in the company, valued at $236,788.65. The disclosure for this sale can be found here. Over the last three months, insiders sold 22,761 shares of company stock worth $193,891. Insiders own 19.10% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This article was first reported by Ticker Report and is owned by of Ticker Report. If you are reading this article on another site, it was illegally stolen and reposted in violation of U.S. and international copyright legislation. The original version of this article can be viewed at https://www.tickerreport.com/banking-finance/3341250/kindred-biosciences-kin-receiving-somewhat-positive-media-coverage-analysis-shows.html.

Kindred Biosciences Company Profile

Kindred Biosciences, Inc is a development-stage biopharmaceutical company. The Company is focused on developing therapies for pets. The Company’s product pipeline consists of small molecules and biologics for a range of indications in dogs, cats and horses. The Company is developing product candidates for over 20 indications and focused on small molecule products and canine and feline biologics products.

Insider Buying and Selling by Quarter for Kindred Biosciences (NASDAQ:KIN)

Receive News & Ratings for Kindred Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kindred Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

$72.27 Million in Sales Expected for Regional Management  This Quarter
$72.27 Million in Sales Expected for Regional Management This Quarter
ManpowerGroup  Stock Price Down 14.5%
ManpowerGroup Stock Price Down 14.5%
TEGNA  Trading Down 5.1%
TEGNA Trading Down 5.1%
OpGen   Shares Down 6%
OpGen Shares Down 6%
Analysts Anticipate Proofpoint, Inc.  Will Announce Earnings of $0.16 Per Share
Analysts Anticipate Proofpoint, Inc. Will Announce Earnings of $0.16 Per Share
Vocera Communications  Expected to Announce Earnings of -$0.05 Per Share
Vocera Communications Expected to Announce Earnings of -$0.05 Per Share


Leave a Reply

© 2006-2018 Ticker Report. Google+.